Epstein-barr-virus-specific immunization

Details Epstein-barr-virus-specific immunization Epstein-barr-virus-specific immunization

2003-06-13

2008-09-09

Campell, Bruce (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C424S185100, C424S186100, C424S204100, C424S229100

Reexamination Certificate

active

07422751

ABSTRACT:
The invention provides materials and methods for using EBV EBNA2 peptide epitopes to treat and/or prevent post-transplant lymphoproliferative disorders (PTLD). The invention also provides compositions and articles of manufacture containing EBNA2 peptide epitopes that can be used to treat and/or prevent PTLD.

REFERENCES:
patent: 5662907 (1997-09-01), Kubo et al.
patent: 5869453 (1999-02-01), Moss et al.
patent: 6162440 (2000-12-01), Hayward et al.
patent: WO 95/24925 (1995-09-01), None
patent: WO95/24925 (1995-09-01), None
patent: WO 01/12215 (2001-02-01), None
Babcock et al., “EBV Persistence in Memory B Cells In Vivo”, Immunity, 1998, 9:395-404.
Cristiano et al., “Molecular conjugates: a targeted gene delivery vector for molecular medicine”, J. Mol. Med., 1995, 73:479-486.
Di Tommaso et al., “Induction of Antigen-Specific Antibodies in Vaginal Secretions by Using a Nontoxic Mutant of Heat-Labile Enterotoxin as a Mucosal Adjuvant”, Infect. Immunity, 1996, 64:974-979.
Finberg, “Epstein-Barr virus-specific T cells for the management of Epstein-Barr virus lymphomas”, Current Opinion Oncology, 2001, 13:349-353.
Hopwood et al., “The role of EBV in post-transplant malignancies: a review”, J. Clin. Pathol., 2000, 53:248-254.
Hsieh et al., “The biology of Epstein-Barr virus in post-transplant lymphoproliferative disease”, Transpl. Infect. Dis., 1999, 1:204-212.
Khanna et al., “Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease”, Proc. Natl. Acad. Sci. USA, 1999, 96(18):10391-10396.
Khanna et al., “Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing”, Int. Immunol., 1997, 9(10):1537-1543.
Khanna et al., “Class I Processing-Defective Burkitt's Lymphoma Cells Are Recognized Efficiently by CD4+EEBV-Specific CTLs”, J. Immunol., 1997, 158(8):3619-3625.
Kieff, “Epstein-Barr Virus and Its Replication” Fields Virology, 1996, Fields, Knipe, and Howley, eds. Lipinocott-Raven Publishers, New York, pp.2343-2396.
Kobayashi et al., “Tumor-reactive T Helper Lymphocytes Recognize a Promiscuous MAGE-A3 Epitope Presented by Various Major Histocompatibility Complex Class II Alleles”, Cancer Res., 2001, 61:4773-4778.
Kobayashi et al., “Defining Promiscuous MHC Class II Helper T-Cell Epitopes for the HER2
eu Tumor Antigen”, Cancer Res., 2000, 60:5228-5236.
Lu et al., “Use of Two Predictive Algorithms of the World Wide Web for the Identification of Tumor-reactive T-Cell Epitopes”, Cancer Res., 2000, 60:5223-5227.
Marsh, “Nomenclature for Factors of the HLA System, Update Mar. 2002”, Human Immunol., 2002, 63:515-516.
Nalesnik, “Clinical and pathological features of post-transplant lymphoproliferative disorders (PTLD)”, Springer Semin. Immunopathol., 1998, 20:325-342.
Nikiforow et al., “CD4+T-Cell Effectors Inhibit Epstein-Barr Virus-Induced B-Cell Proliferation”, J. Virol., 2001, 75(8):3740-3752.
Paya et al., “Epstein-Barr Virus-Induced Posttransplant Lymphoproliferative Disorders”, Transplantation, 1999, 68(10):1517-1525.
Penix et al., “Two Essential Regulatory Elements in the Human Interferon γ Promoter Confer Activation Specific Expression in T Cells”, J. Experim. Med., 1993, 178:1483-1496.
Rickinson et al., “Human Cytotoxic T Lymphocyte Responses to Epstein-Barr Virus Infection”, Ann. Rev. Immunol., 1997, 15405-31.
Rowe, “Epstein-Barr Virus Immortalization and Latency”, Front. Biosci., 1999, 4:D346-371.
Sigal et al., “Cyclosporin A, FK-506, and Rapamycin: Pharmacologic Probes of Lymphocyte Signal Transduction”, Annu. Rev. Immunol., 1992, 10:510-560.
Southwood et al., “Several Common HLA-DR Types Share Largely Overlapping Peptide Binding Repertoires”, J. Immunol., 1998, 160:3363-3373.
Thomson et al., “Targeting a Polyepitope Protein Incorporating Multiple Class II-Restricted Viral Epitopes to the Secretory/Endocytic Pathway Facilitates Immune Recognition by CD4+Cytotoxic T Lymphocytes: a Novel Approach to Vaccine Design”, J. Virol., 1998, 72(3):2246-2252.
Thompson et al., “cis-Acting Sequences Required for Inducible Interleukin-2 Enhancer Function Bind a Novel Ets-Related Protein, Elf-1”, Mol. And Cell. Biol., 1992, 12(3):1043-1053.
Todd et al., “Transcription of the Interleukin 4 Gene Is Regulated by Multiple Promoter Elements”, J. Exp. Med., 1993, 177:1663-1674.
Yamamoto et al., “Mutants in the ADP-ribosylatransferase Cleft of Cholera Toxin Lack Diarrheagenicity by Retain Adjuvanticity”, J. Exp. Med., 1997, 185(7):1203-1210.

Affiliated with

Also associated with

Rating

Epstein-barr-virus-specific immunization does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Epstein-barr-virus-specific immunization, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Epstein-barr-virus-specific immunization will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3978854